Nasdaq Biotechnology Ishares (IBB) 373.58 $IBB Cramer --

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 373.58 $IBB

Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
at The Street - Mon Jul 27, 10:38AM CDT
Jim Cramer is not hungry for GrubHub and says Biogen is turning into a battle royale for biotech investors.
BIIB: 309.43 (+9.40), GRUB: 31.01 (-2.78), XBI: 251.78 (-3.60), IBB: 373.58 (-4.00), REGN: 540.03 (-1.82), CELG: 132.56 (-2.34)

1 ETF That’s Crushing Even Warren Buffett
George Budwell, The Motley Fool - Motley Fool - Sat Jul 25, 6:07AM CDT
Source: Flickr via Fortune Live Media Berkshire Hathaway   is a legendary holding company among investors due to its 50-year history of averaging a staggering 19% annual return . To put this amazing feat into context, Berkshire's average annual...
GILD: 110.54 (-2.29), IBB: 373.58 (-4.00), CELG: 132.56 (-2.34)

SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 4.11% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:14PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $375.96 to a high of $389.00. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $388.91 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 4.11% Sell Off
Comtex SmarTrend(R) - Fri Jul 24, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $375.96 to a high of $389.00. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $388.91 on volume of 3.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)

Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
Marketwired - Thu Jul 23, 8:01AM CDT
Vista Partners announced today that it has initiated coverage on Immune Pharmaceuticals Inc. (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. ('IMNP', headquartered in New York, is a clinical stage biopharmaceutical company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. IMNP's lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with future studies planned for Crohn's disease, severe asthma, NASH and atopic dermatitis." Mr. Silver continues, "On July 14, 2015 Celgene Corporation (CELG) and Receptos, Inc. (RCPT) announced the signing of a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2B, net of cash acquired. The transaction adds Ozanimod, which has demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), among others. Having Receptos as a comparison may be beneficial to IMNP as we may now be able to understand from a monetary perspective the value a compound intended to treat UC amongst others is worth."
IBB: 373.58 (-4.00), IMNP: 1.74 (-0.10), CELGZ: 2.00 (-0.06)

iShares Nasdaq Biotechnology Index Fund (IBB) : Take profit @ $390
Trading Central - Wed Jul 15, 1:54PM CDT
A gravestone doji is taking place, calling for a trend reversal. We close our long position @ 390. Performance: +3.28%.
IBB: 373.58 (-4.00)

These 2 Biotech Stocks Cratered in 2015 -- Is 1 Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Jul 15, 9:04AM CDT
Source: Cancer Institute of Columbia For the most part, biotech stocks have been having a great 2015. The iShares Nasdaq Biotech Index , for instance, has essentially clobbered the broader markets so far this year: Per usual, however,...
IBB: 373.58 (-4.00), AAVL: 14.29 (-0.44), PBYI: 84.69 (-4.60)

'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 94.17 (-2.78), FBT: 123.85 (-1.42), XBI: 251.78 (-3.60), AMGN: 165.54 (+6.95), IBB: 373.58 (-4.00), INTC: 28.35 (+0.29), CELG: 132.56 (-2.34), NFLX: 106.43 (-2.91), SPY: 206.79 (-1.21), GILD: 110.54 (-2.29), KITE: 68.86 (+0.14), RCPT: 227.09 (-0.91), JUNO: 47.80 (-2.36), TWTR: 34.70 (-0.72), AAPL: 122.77 (-1.73), Z: 76.91 (-2.64)

As Biotech Beats, 6 Top ETF Picks For Rest Of 2015
at Investor's Business Daily - Tue Jul 14, 5:38PM CDT
Biotechnology and pharmaceutical ETFs powered ahead in the past month, handing profits-on-steroids to investors. A wave of mergers, robust pipelines and busier-than-ever hospitals continue to drive these industries forward. The iShares Nasdaq...
SPY: 206.79 (-1.21), EFAV: 66.24 (-0.36), OIL: 9.22 (-0.26), AGG: 109.26 (+0.14), ILMN: 217.27 (-3.83), IBB: 373.58 (-4.00), SHY: 84.85 (+0.06), VNQ: 78.21 (+0.14), FV: 24.65 (-0.23), SDY: 75.93 (-0.17)

Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015 - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 8:30AM CDT
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015
XOP: 37.44 (-1.15), XT: 25.25 (-0.25), UBIO: 18.24 (-0.67), XBI: 251.78 (-3.60), IBB: 373.58 (-4.00), LABU: 46.23 (-2.40), ZBIO: 20.79 (+0.66), CHAD: 48.76 (+3.96), YLCO: 13.34 (+0.15), LABD: 30.37 (+1.20), DRIP: 83.98 (+6.73), ASHR: 39.16 (-3.95), GUSH: 16.27 (-1.59)

iShares Nasdaq Biotechnology Index Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 13, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 373.58 (-4.00)

Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Mon Jul 13, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 373.58 (-4.00)

It's Time for Investors to Focus on Individual Stocks, Not Macro Events
at The Street - Mon Jul 13, 1:42PM CDT
The 'Fast Money Halftime' trading panel says that in this weak macro market, momentum stocks, individual companies and specific sectors should be the theme for investors, not broad-based index funds.
FIT: 43.93 (-1.61), GREK: 9.33 (-0.42), XBI: 251.78 (-3.60), C: 57.96 (-0.74), IBB: 373.58 (-4.00), BAC: 17.67 (-0.23), TLT: 122.04 (+0.65), MS: 39.25 (-0.35), NFLX: 106.43 (-2.91), SPY: 206.79 (-1.21), GS: 205.02 (-2.33), JPM: 68.01 (-0.90), QQQ: 110.18 (-0.92), DIA: 174.23 (-1.29), IWM: 120.57 (-1.01), XLF: 24.94 (-0.18)

Trader's Notebook: Transport ETF Could Bounce Back
at The Street - Thu Jul 09, 8:00AM CDT
The iShares Transportation Average ETF (IYT) has suffered in recent months, but may finally be nearing a bit of support.
YANG: 92.20 (+9.72), IBB: 373.58 (-4.00), YINN: 27.66 (-3.66), IYT: 144.41 (-0.22), FXI: 40.13 (-1.61)

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 2.85%
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)

After Yesterday's Decline of 2.85%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 373.58 (-4.00)

3 Stocks to Buy in a Market Crash
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 08, 10:55AM CDT
The last five years have been an absolute dream particularly for biotech investors; shares of the  iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) have scorched the returns of the market over that time period, up more than 400% when the...
ISIS: 53.68 (+0.53), GILD: 110.54 (-2.29), IBB: 373.58 (-4.00), CELG: 132.56 (-2.34)

Uncertainty Escalates After Greek Referendum
David Fry - at Seeking Alpha - Mon Jul 06, 11:14PM CDT
At this point words fail me once again. What will happen to Greece and their EU partners, no one knows. For now it's a cancer growing on both Greece and many world stock indexes. China is more alarming after the PBOC intervened in markets to no...
XLB: 44.58 (-0.50), GREK: 9.33 (-0.42), IBB: 373.58 (-4.00), EWO: 16.15 (-0.15), TLT: 122.04 (+0.65), EEM: 36.36 (-0.70), XLP: 49.65 (-0.03), SPY: 206.79 (-1.21), ITB: 27.09 (-0.08), IYR: 74.11 (+0.16), XLI: 52.64 (-0.26), SLV: 13.92 (-0.10), FXE: 108.90 (+1.15), XLF: 24.94 (-0.18), GDX: 13.57 (-0.51), JJC: 27.59 (-0.54), XLE: 68.51 (-1.00), FXI: 40.13 (-1.61), USO: 15.65 (-0.38), DBC: 15.83 (-0.31), DBA: 21.33 (-0.37), XLY: 78.26 (-0.59), FXY: 78.76 (+0.35), EZU: 38.10 (-0.35), XLU: 42.87 (+0.54), HAO: 26.11 (-1.99), UUP: 25.25 (-0.20), XRT: 96.33 (-0.81), XLV: 74.78 (-0.07), IEV: 43.83 (-0.35), GLD: 104.86 (-0.49), EPI: 21.52 (-0.41), RSX: 16.52 (-0.43), EFA: 63.42 (-0.47), EWZ: 28.05 (-0.45)

The Medicines Company Is Rallying Despite Unfavorable Ruling In Patent Case
Emerging Equities - at Seeking Alpha - Mon Jul 06, 6:51PM CDT

MDCO: 33.39 (-0.43), MYL: 56.37 (-9.57), IBB: 373.58 (-4.00)

Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.28 (-0.23), SGYP: 8.19 (+0.28), MNK: 123.08 (-0.74), BIIB: 309.43 (+9.40), OCAT: 4.63 (-0.06), VRX: 257.30 (+5.38), PRGO: 193.60 (+7.10), VRTX: 123.23 (-2.27), GALT: 2.63 (-0.06), IBB: 373.58 (-4.00), MNKD: 4.77 (-0.21), HNT: 65.60 (-0.07), CELG: 132.56 (-2.34), CNC: 69.10 (+0.06), JNJ: 98.28 (-0.87), MDCO: 33.39 (-0.43), GILD: 110.54 (-2.29), GERN: 4.08 (-0.03), JUNO: 47.80 (-2.36), BXLT: 30.60 (-0.29), EXEL: 5.44 (-0.15), NVS: 101.54 (-0.26)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 2

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 4

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 5

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 7

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 6

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 2

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Eye Class Action Lawsuit Against Smart Digital Group

Updated Category News Views 142

Class Action Lawsuit Overview Against Smart Digital Group Ltd. The Rosen Law Firm, recognized for advocating for investor rights globally, has initiated a class action lawsuit aimed at purchasers of securities from Smart Digital Group Ltd. (NASDAQ: SDM). This lawsuit encompasses transactions that occurred between May 5, 2025, and September 26, 2025. Investors who made...

Continue Reading
Join the Class Action Against Zeta Global Holdings Today

Updated Category News Views 108

Join the Class Action Against Zeta Global Holdings Levi & Korsinsky, LLP is reaching out to concerned investors in Zeta Global Holdings Corp. regarding a class action lawsuit that could affect many shareholders. This lawsuit aims to recover losses incurred by those negatively impacted by alleged securities fraud during a specific timeframe. Understanding the Class Action...

Continue Reading
EverBank Strengthens Equipment Finance with New Division

Updated Category News Views 209

EverBank Expands Its Equipment Finance Horizons EverBank is embarking on an exciting new journey by launching a Corporate Asset Finance division, enhancing its equipment finance capabilities significantly. This innovative step is set to offer structured equipment loans and leases to large and middle-market companies, ensuring that they receive the support they need to...

Continue Reading
USA Health and RLDatix Team Up for Enhanced Patient Safety

Updated Category News Views 122

USA Health and RLDatix Team Up for Enhanced Patient Safety In a significant development in the healthcare sector, USA Health has announced an expansion of its partnership with RLDatix, a trailblazer in healthcare operations software. This collaboration is designed to foster a safer healthcare environment, ensuring patients receive the highest standard of care. Empowering...

Continue Reading
Exciting Advancements in COVID-19 Vaccine Technology by Soligenix

Updated Category News Views 289

Soligenix’s CiVax™: A New Approach to COVID-19 Vaccination In a remarkable leap forward in the fight against COVID-19, Soligenix, Inc. (NASDAQ: SNGX), a biopharmaceutical company dedicated to rare disease treatments, has announced significant findings about its innovative vaccine candidate, CiVax™. This thermostabilized subunit vaccine has demonstrated promising...

Continue Reading